rTMS for Neuropathic Pain After Spinal Cord Injury
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether a non-invasive treatment called repetitive transcranial magnetic stimulation (rTMS) can reduce pain for individuals with nerve pain following a spinal cord injury. rTMS uses magnetic fields to stimulate specific brain areas, and participants will undergo these sessions over four weeks. The trial seeks individuals diagnosed by a doctor with a spinal cord injury who have experienced neuropathic pain for at least three months, affecting daily activities. As an unphased trial, it offers participants the chance to contribute to innovative research that could lead to new pain management solutions.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this technique is safe for treating neuropathic pain after spinal cord injury?
Research shows that repetitive transcranial magnetic stimulation (rTMS) is generally safe for people. This non-invasive technique uses magnets to stimulate the brain. Studies have found it carries a low risk of side effects. While rTMS can help manage pain, one study found it was not more effective than a placebo for some types of pain. However, it remains well-tolerated. Most people do not experience serious side effects. Some might feel mild discomfort or a headache, but these usually resolve quickly. Overall, rTMS is considered a safe option for those looking to reduce nerve-related pain.12345
Why are researchers excited about this trial?
Repetitive Transcranial Magnetic Stimulation (rTMS) is unique because it offers a non-invasive approach to manage neuropathic pain after spinal cord injury by using magnetic fields to stimulate nerve cells in the brain. Unlike traditional treatments like medications that target the symptoms of pain, rTMS focuses directly on altering brain activity in the dorsolateral prefrontal cortex, which can help modulate pain perception. Researchers are excited about this treatment because it can be precisely targeted and adjusted to each individual's needs, potentially offering pain relief with fewer side effects compared to conventional pharmaceutical options.
What evidence suggests that rTMS is effective for neuropathic pain after spinal cord injury?
Research has shown that the effectiveness of repetitive transcranial magnetic stimulation (rTMS) for treating nerve pain after a spinal cord injury remains unclear. In this trial, participants will undergo rTMS sessions to evaluate its potential benefits. Some studies suggest that rTMS can relieve this type of pain without surgery. However, other research found that rTMS did not outperform a placebo for individuals with nerve pain from spinal cord injuries. This mixed evidence indicates that while rTMS might help some people, its effectiveness can vary. More research is needed to confirm its benefits for this specific pain.12467
Who Is on the Research Team?
Chantel T Debert, MD MSc FRCPC CSCN
Principal Investigator
University of Calgary
Are You a Good Fit for This Trial?
This trial is for adults aged 18-75 with neuropathic pain lasting at least 3 months due to a spinal cord injury. Candidates must not have other conditions causing the pain, no prior TMS therapy, and no contraindications like pacemakers, metal implants in the head, seizures, severe psychiatric disorders, or uncontrolled major diseases.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo high frequency rTMS sessions 5 days a week for 4 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Repetitive Transcranial Magnetic Stimulation (rTMS)
Repetitive Transcranial Magnetic Stimulation (rTMS) is already approved in United States, European Union, Canada, Japan for the following indications:
- Depression
- Smoking cessation
- Depression
- Depression
- Depression
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Calgary
Lead Sponsor